Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Together, these studies offer valuable new evidence supporting the use of GLP-1 receptor agonists for kidney and cardiovascular protection in individuals at risk for or with established chronic kidney disease
not FDA-approved as of January 2025 Best Phase 2 result / 24.2% mean body weight loss at 48 weeks (12 mg dose, N=338 trial) Extended estimate / 28.7% mean weight loss projected at 68 weeks in Phase 2 modeling Dosing schedule / Once weekly subcutaneous injection (doses 1 mg through 12 mg tested) Comparator benchmark / Semaglutide 2.4 mg: 14.9% at 68 weeks (STEP-1, N=1,961) Comparator benchmark / Tirzepatide 15 mg: 20.9% at 72 weeks (SURMOUNT-1, N=2,539) Primary side effects / Nausea, vomiting, diarrhea, constipation (dose-dependent) Phase 3 status / Phase 3 program (TRIUMPH trials) enrolling as of 2024 Manufacturer / Eli Lilly and Company What Is Retatrutide
Start Your Weight Loss Journey at Emerson Medical on Staten Island Ready to explore how GLP-1 medications like semaglutide can transform your weight management journey
By engaging multiple mechanisms in the central nervous system, GLP-1RAs may directly or indirectly improve cognitive and motor functions
Former president and COO of Life Time, Jeff now leads the companys MIORA longevity clinic pairing fitness and nutrition programs with medical and aesthetic treatments
Compounded medications are not FDA-approved, but they are a legal and widely used option when commercially available alternatives are inaccessible or cost-prohibitive
